Acute Post-Operative Pain - Javelin Enrolls First Patient In An Open Label Safety Study Of Dyloject
Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today announced that it had enrolled the first patient in a planned Phase 3, single-arm, open label observational safety study for its injectable NSAID, Dyloject? (diclofenac sodium).
More: continued here
Filed under: Pain / Anesthetics on October 1st, 2008